ArticleJournal of medicinal chemistry2023
Discovery of Nanomolar DCAF1 Small Molecule Ligands.
Open access · hybridAbstract read
In one paragraph
Article in Journal of medicinal chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
9.1field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 59 citations in OpenAlex.
- Context matters in PROTAC design: navigating the trade-off between degradation and developability.Journal of enzyme inhibition and medicinal chemistry · 2026Review
- Artificial intelligence empowers targeted protein degradation: Core technological innovations, multi-scenario applications, and translational prospects.Smart molecules : open access · 2026Review
- On the Scope of DCAF1-Recruiting PROTACs Degrading Protein Kinases.Journal of medicinal chemistry · 2026Article
- Self-Dimerization Induced Proximity Targeting Chimeras (SDIPTAC) Lead to DCAF1 Loss of Function and Inhibition of HIV Replication.Journal of medicinal chemistry · 2026Article
- Methods to Study the Molecular Mechanism and Drive the Design of Protein Degraders.Chemical reviews · 2026Review
- Targeted Protein Degradation in Lung Cancer: The Emerging Role of PROTAC Technology and E3 Ligases.Current medicinal chemistry · 2026Review
- Enantioselective protein affinity selection mass spectrometry (E-ASMS).Nature communications · 2025Article
- Mode of action of a DCAF16-recruiting targeted glue that can selectively degrade BRD9.Nature communications · 2025Article
- Protein-ligand data at scale to support machine learning.Nature reviews. Chemistry · 2025Review
- OICR-41103 as a chemical probe for the DCAF1 WD40 domain.Communications biology · 2025Article
- Implications of frequent hitter E3 ligases in targeted protein degradation screens.Nature chemical biology · 2025Review
- Inhibitors of SAMHD1 Obtained from Chemical Tethering to the Guanine Antiviral Acyclovir.Biochemistry · 2025Article
- Discovery of DCAF16 Binders for Targeted Protein Degradation.ACS chemical biology · 2025Article
- Toward target 2035: EUbOPEN - a public-private partnership to enable & unlock biology in the open.RSC medicinal chemistry · 2025Article
- A Target Class Ligandability Evaluation of WD40 Repeat-Containing Proteins.Journal of medicinal chemistry · 2025Article
- Crystal structures of DCAF1-PROTAC-WDR5 ternary complexes provide insight into DCAF1 substrate specificity.Nature communications · 2024Article
- Chemical Proteomics-Guided Discovery of Covalent Ligands for Cancer Proteins.Annual review of cancer biology · 2024Article
- The cross talk of ubiquitination and chemotherapy tolerance in colorectal cancer.Journal of cancer research and clinical oncology · 2024Review
- DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance.Nature communications · 2024Article
- Pharmacophore-Based Machine Learning Model To Predict Ligand Selectivity for E3 Ligase Binders.ACS omega · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors at 5 institutions in 3 countries.
Alice Shi Ming LiStructural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.ORCID 0000-0003-1093-9698
Serah KimaniStructural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
Brian WilsonDrug Discovery Program, Ontario Institute for Cancer Research, Toronto, Ontario M5G 0A3, Canada.
Mahmoud NoureldinDrug Discovery Program, Ontario Institute for Cancer Research, Toronto, Ontario M5G 0A3, Canada.
Héctor González-ÁlvarezDrug Discovery Program, Ontario Institute for Cancer Research, Toronto, Ontario M5G 0A3, Canada.
Ahmed MamaiDrug Discovery Program, Ontario Institute for Cancer Research, Toronto, Ontario M5G 0A3, Canada.
Laurent HofferDrug Discovery Program, Ontario Institute for Cancer Research, Toronto, Ontario M5G 0A3, Canada.
John P GuilingerX-Chem Inc., Waltham, Massachusetts 02453, United States.
Ying ZhangX-Chem Inc., Waltham, Massachusetts 02453, United States.
Moritz von RechenbergRelay Therapeutics, Cambridge, Massachusetts 02139, United States.
Jeremy S DischRelay Therapeutics, Cambridge, Massachusetts 02139, United States.ORCID 0000-0002-0357-1672
Christopher J MulhernRelay Therapeutics, Cambridge, Massachusetts 02139, United States.
Belinda L SlakmanRelay Therapeutics, Cambridge, Massachusetts 02139, United States.
John W CuozzoRelay Therapeutics, Cambridge, Massachusetts 02139, United States.ORCID 0000-0002-6229-0395
Aiping DongStructural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
Gennady PodaDrug Discovery Program, Ontario Institute for Cancer Research, Toronto, Ontario M5G 0A3, Canada.
Mohammed MohammedDrug Discovery Program, Ontario Institute for Cancer Research, Toronto, Ontario M5G 0A3, Canada.
Punit SaraonDrug Discovery Program, Ontario Institute for Cancer Research, Toronto, Ontario M5G 0A3, Canada.
Manish MittalPiramal Discovery Solutions, Pharmaceutical Special Economic Zone, Ahmedabad, Gujarat 382213, India.
Pratik ModhPiramal Discovery Solutions, Pharmaceutical Special Economic Zone, Ahmedabad, Gujarat 382213, India.
Vaibhavi RathodPiramal Discovery Solutions, Pharmaceutical Special Economic Zone, Ahmedabad, Gujarat 382213, India.
Bhashant PatelPiramal Discovery Solutions, Pharmaceutical Special Economic Zone, Ahmedabad, Gujarat 382213, India.
Suzanne AcklooStructural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
Vijayaratnam SanthakumarStructural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.ORCID 0000-0002-7001-557X
Magdalena M SzewczykStructural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
Dalia Barsyte-LovejoyStructural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
Cheryl H ArrowsmithStructural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.ORCID 0000-0002-4971-3250
Richard MarcellusDrug Discovery Program, Ontario Institute for Cancer Research, Toronto, Ontario M5G 0A3, Canada.
Marie-Aude GuiéX-Chem Inc., Waltham, Massachusetts 02453, United States.
Anthony D KeefeX-Chem Inc., Waltham, Massachusetts 02453, United States.
Peter J BrownStructural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.ORCID 0000-0002-8454-0367
Levon HalabelianStructural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.ORCID 0000-0003-4361-3619
Rima Al-AwarDrug Discovery Program, Ontario Institute for Cancer Research, Toronto, Ontario M5G 0A3, Canada.
Masoud VedadiStructural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.ORCID 0000-0002-0574-0169
Ontario Institute for Cancer Research · CAUniversity of Toronto · CARelay Therapeutics (United States) · USPiramal (India) · INUniversity Health Network · CA
Funding
User Training and OutreachP30GM124165 · NIGMS · CORNELL UNIVERSITY · PI Nozomi Ando, J Christopher Fromme · 2018 to 2026
$34.2MNIGMS NIH HHS P30 GM124165
Abstract
DCAF1 is a substrate receptor of two distinct E3 ligases (CRL4
Indexed as
NeoplasmsUbiquitin-Protein LigasesCarrier ProteinsHumansLigandsCarrier ProteinsLigandsUbiquitin-Protein Ligases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.